Micardisplus

Telmisartan/Hydrochlorothiazide, the active ingredient in Micardisplus, is an angiotensin II receptor blocker / thiazide diuretic presented as an oral tablet for oral use. It treats hypertension in adult patients who need blood pressure control.

GNH USA supplies Micardisplus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Micardisplus is indicated for the management of hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: reduces systolic and diastolic blood pressure, helping to prevent stroke and heart attack. - Secondary hypertension due to renal disease: assists in controlling pressure when other causes are present. - Hypertension requiring combination therapy: provides both ARB and diuretic effects in a single tablet.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate tension‑type pain. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Electrolyte imbalance: particularly low potassium levels.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Acute kidney injury: sudden decline in renal function. - Significant hypotension: marked drop in blood pressure causing faintness. - Hyperkalemia: elevated potassium that can affect heart rhythm. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider the following precautions: - Renal function: assess creatinine and eGFR, adjust if impaired. - Electrolytes: monitor serum potassium and sodium regularly. - Pregnancy: contraindicated (Category D) due to fetal risk. - Concomitant ACE inhibitor or ARB therapy: avoid combined use to reduce renal injury risk. - Severe hepatic impairment: use with caution or avoid. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Micardisplus may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Aliskiren in diabetic patients: increased risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity. - NSAIDs: can blunt antihypertensive effect and affect renal function. - ACE inhibitors or other ARBs: combined use may cause renal impairment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: additive blood‑pressure lowering, monitor for excessive hypotension. - Calcium channel blockers: may enhance hypotensive response. - Antidiabetic agents: blood‑glucose levels may fall, requiring dose adjustment.